Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 28, 2015 8:10 AM ET


Company Overview of Boston Therapeutics, Inc.

Company Overview

Boston Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements to address blood sugar management and inflammatory diseases. It produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy post-meal blood glucose levels. The company’s lead product candidates include BTI-320, a non-systemic, carbohydrate based compound, which has completed a Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic patients; and IPOXYN, an injectable anti-necrosis drug candidate ...

1750 Elm Street

Suite 103

Manchester, NH 03104

United States

Founded in 2009

7 Employees





Key Executives for Boston Therapeutics, Inc.

Chairman, Chief Executive Officer, Founder, Chief Financial Officer, Treasurer and Member of The Scientific Advisory Board
Age: 61
Total Annual Compensation: $100.0K
Compensation as of Fiscal Year 2014.

Boston Therapeutics, Inc. Key Developments

Boston Therapeutics, Inc. announced delayed 10-Q filing

On 11/16/2015, Boston Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Boston Therapeutics, Inc. Announces Executive Changes

On September 1, 2015, the Chief Financial Officer of Boston Therapeutics, Inc., Tony Squeglia, submitted his letter of resignation as an officer and employee of the company for health reasons. Until a successor is appointed, the company's Chief Executive Officer, David Platt, will serve as Chief Financial Officer.

Boston Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Boston Therapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $38,851 compared to revenue of $21,391 a year ago. The increase is primarily related to larger shipments to Advance Pharmaceutical as compared to the three months ended June 30, 2014. Net loss was $686,238 or $0.02 per basic and diluted share, against $1,211,095 or $0.03 per basic and diluted share a year ago. Operating loss was $511,237 compared to $1,206,107 a year ago. For the six months, the company reported revenue of $90,180 compared to revenue of $65,218 a year ago. Net loss was $1,362,525 or $0.04 per basic and diluted share, against $2,778,239 or $0.07 per basic and diluted share a year ago. Operating loss was $1,246,110 compared to $2,764,237 a year ago.

Similar Private Companies By Industry

Company Name Region
Dobbs Consulting, LLC United States
Janssen Biotech, Inc. United States
Vitreoretinal Technologies, Inc. United States
Medican Systems Inc. United States
Citron Pharma LLC United States

Recent Private Companies Transactions

Private Placement
September 24, 2015
Private Placement
March 18, 2015
Private Placement
March 13, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Boston Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at